Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment
- PMID: 1854511
- DOI: 10.3109/02841869109092414
Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment
Abstract
Several previous reports suggest an association between treatment of patients with interferon-alpha (IFN-alpha) and development of autoantibodies and autoimmune disease. We here summarize the experience from a group of 135 patients with midgut carcinoid tumors treated with natural leukocyte IFN-alpha or recombinant IFN-alpha (rIFN-alpha). An unusual high incidence of antimicrosomal antibodies (MsAb) or anti-thyroglobulin antibodies (TgAb) and thyroid disease manifested as hyperthyroidism, hypothyroidism or a biphasic Hashimoto-like disease was seen, with female predominance. The incidence of antinuclear antibodies (ANA) was also increased, but equally in both sexes. Antibodies to parietal cells were found in 5 cases and 4 patients with pernicious anemia were detected. Two patients developed vasculitis of leukocytoclastic type and one a syndrome resembling systemic lupus erythematosus. Some patients treated with rIFN-alpha develop anti-IFN antibodies. Such antibodies may also be autoantibodies reacting with autologous IFN-alpha. They can neutralize the biologic activity of administrated IFN preparation and cause therapeutic failure. The implications of the various autoimmune manifestations during IFN-alpha treatment are discussed.
Similar articles
-
Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors.Ann Intern Med. 1991 Aug 1;115(3):178-83. doi: 10.7326/0003-4819-115-3-178. Ann Intern Med. 1991. PMID: 2058872
-
Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.J Interferon Res. 1989 Sep;9 Suppl 1:S45-9. J Interferon Res. 1989. PMID: 2809277
-
Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.J Natl Cancer Inst. 1989 Apr 5;81(7):531-5. doi: 10.1093/jnci/81.7.531. J Natl Cancer Inst. 1989. PMID: 2466128
-
Natural autoantibodies to interferons.J Interferon Cytokine Res. 1997 Jul;17 Suppl 1:S51-3. J Interferon Cytokine Res. 1997. PMID: 9241617 Review.
-
Immune-mediated complications during interferon therapy in hematological patients.Acta Haematol. 2002;107(3):133-44. doi: 10.1159/000057631. Acta Haematol. 2002. PMID: 11978934 Review.
Cited by
-
Genetics of SLE: functional relevance for monocytes/macrophages in disease.Clin Dev Immunol. 2012;2012:582352. doi: 10.1155/2012/582352. Epub 2012 Oct 16. Clin Dev Immunol. 2012. PMID: 23227085 Free PMC article. Review.
-
Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus.J Immunol. 2014 Feb 1;192(3):906-18. doi: 10.4049/jimmunol.1302112. Epub 2013 Dec 30. J Immunol. 2014. PMID: 24379124 Free PMC article.
-
B cells in glomerulonephritis: focus on lupus nephritis.Semin Immunopathol. 2007 Nov;29(4):337-53. doi: 10.1007/s00281-007-0092-1. Epub 2007 Oct 18. Semin Immunopathol. 2007. PMID: 17943287 Review.
-
Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis.Dig Dis Sci. 1996 Aug;41(8):1672-7. doi: 10.1007/BF02087923. Dig Dis Sci. 1996. PMID: 8769300
-
[Interferon therapy and autoimmunity].Med Klin (Munich). 1997 May 15;92(5):265-72. doi: 10.1007/BF03045081. Med Klin (Munich). 1997. PMID: 9244832 Review. German.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical